Announced details
Drug discovery, next-generation pharmaceuticals, pain, eye disorders, bone diseases, and new non-pharmaceutical applications of aptamers
フェアリサーチ株式会社 prepared an analyst report on the Company. It was published in the Stock Forecast column of 株式会社アイフィスジャパン. Capital and personnel relationships are Not disclosed.
フェアリサーチ株式会社: A company that researches, analyzes and promotes awareness of corporate value, based on more than 35 years of experience in the investment management industry. 株式会社アイフィスジャパン: Listed as the publisher of the Stock Forecast column. Other information on the locations, representatives, capital and year of establishment is Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Analyst report by フェアリサーチ株式会社; Stock Forecast column of 株式会社アイフィスジャパン
| Item | Details |
|---|---|
| Names of Products / Services Covered | DDS aptamers, RBM-007, RiboART System |
| Counterparty | フェアリサーチ株式会社, 株式会社アイフィスジャパン |
| Counterparty overview | フェアリサーチ株式会社: A company that researches, analyzes and promotes awareness of corporate value, based on more than 35 years of experience in the investment management industry. 株式会社アイフィスジャパン: Listed as the publisher of the Stock Forecast column. Other information on the locations, representatives, capital and year of establishment is Not disclosed. |
| Relationship with the Company | フェアリサーチ株式会社 prepared an analyst report on the Company. It was published in the Stock Forecast column of 株式会社アイフィスジャパン. Capital and personnel relationships are Not disclosed. |
| Launch date | 18 August 2026 (already released) |
| Applicable area | Drug discovery, next-generation pharmaceuticals, pain, eye disorders, bone diseases, and new non-pharmaceutical applications of aptamers |
| Source | Analyst report by フェアリサーチ株式会社; Stock Forecast column of 株式会社アイフィスジャパン |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.An analyst report based on research and analysis from a third-party perspective was published.